SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is trending as investors anticipate earnings, with the community debating whether strong results are already priced in or if the stock will skyrocket. Discussions include valuation concerns, potential for a stock split, and comparisons to other high-growth tech companies. Some traders are also pointing to possible catalysts beyond earnings, such as new government contracts and partnerships in the AI space.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors anticipate upcoming earnings and potential FDA updates, specifically regarding its gene therapy Elevidys. The community is actively discussing predictions for the earnings report and speculating on the likelihood of positive surprises. Traders are also closely monitoring the overall healthcare sector and potential buyout scenarios for the company.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

Enveric Biosciences Inc

Enveric Biosciences ($ENVB) is trending as traders discuss a potential short squeeze due to its low float and recent news, drawing comparisons to past squeezes like $BYND. Community members are actively speculating on potential price targets and anticipating a significant move, while also referencing a recent reverse stock split.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as investors discuss a potential breakout, with community members pointing to strong demand and volume spikes. Anticipation is building around potential catalysts, including activity from Asian markets and speculation about tariff impacts. Some traders believe the stock is undervalued and poised for a significant rebound despite recent struggles, while others express concerns about the brand's direction and market competition.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

$SLAP is trending as the community rallies around its meme-driven culture and real-world partnerships, including sponsorships in sports and streaming. Community members express enthusiasm, highlighting the token's active presence and potential for growth. The focus remains on community support and shared bullish sentiment.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

Cipher Mining is trending as investors eagerly await earnings and a potential Black Pearl deal announcement, with the community anticipating significant news. Discussions revolve around the company's shift towards AI infrastructure and its advantageous position in securing deals with major players, reflecting broader interest in AI-related stocks. Positive sentiment is fueled by comparisons to industry peers like IREN, which recently secured a major deal, boosting hopes for CIFR's growth potential.

Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.

Terns Pharmaceuticals Inc

Terns Pharmaceuticals is trending due to positive Phase 1 data for their leukemia drug TERN-701, leading to analyst upgrades and optimism about its potential to disrupt the CML treatment landscape; the community is discussing the implications of the data and potential future catalysts, with some speculating about a possible buyout. Despite a recent discontinuation of their GLP-1 program, TERN's stock is experiencing a surge, with investors focusing on the remaining oncology asset.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

ONDS is trending amid discussions about its recent acquisitions and strategic direction, with community members debating whether these moves will translate into revenue growth.  The stock's volatile price action and a recent offering have fueled debate about its valuation and potential, while some are optimistic about its positioning in the drone and defense sectors.  Chatter also revolves around speculation on the potential impact of government shutdowns and upcoming news.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure ($QURE) is trending due to a significant shift in the FDA's stance on its Huntington's disease gene therapy, AMT-130, leading to a sharp stock decline. The community is debating the impact of this regulatory setback, particularly the FDA's altered data requirements, and discussing potential buying opportunities amid the volatility, with some speculating about a possible acquisition. This situation has sparked broader concerns about the FDA's consistency and its effect on biotech innovation.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors discuss its potential, particularly surrounding its QNX technology and partnerships with companies like NVIDIA. Community members are debating the impact of these collaborations and the overall direction of the stock, with some expressing bullish sentiment and anticipating a breakout. Discussions also include the influence of market manipulation and the significance of upcoming earnings reports.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Standard BioTools (LAB) Reports Q2 Loss, Tops Revenue Estimates

Standard BioTools (LAB) delivered earnings and revenue surprises of 0.00% and +5.35%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Doximity (DOCS) Q1 Earnings and Revenues Top Estimates

Doximity (DOCS) delivered earnings and revenue surprises of +16.13% and +4.47%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Illumina Stock May Benefit From New Agreement to Acquire SomaLogic

ILMN jumps 2.9% after striking a $350M deal to acquire SomaLogic and boost its fast-growing multiomics strategy.

Standard BioTools And 2 Other Penny Stocks Executives Are Buying

Standard BioTools And 3 Other Stocks Under $3 Executives Are Buying

Standard BioTools initiated with bullish view at Jefferies, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan  Platform for Translational Medicine Research

SOUTH SAN FRANCISCO, Calif., April 03, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose Unleashing tools to accelerate breakthroughs in human health today...

Standard BioTools (NASDAQ:LAB) Shares Up 6.9%

Standard BioTools Inc. (NASDAQ:LAB  Get Free Report)s stock price rose 6.9% on Thursday . The stock traded as high as $2.81 and last traded at $2.80. Approximately 954,671 shares were...

Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock

SOUTH SAN FRANCISCO, Calif., March 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. ( Standard BioTools or the Company ) (Nasdaq: LAB) today announced that it has exchanged all outstanding...

Standard BioTools Inc. (LAB) Q4 2023 Earnings Call Transcript

Standard BioTools Inc. (LAB) Q4 2023 Earnings Call Transcript...

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Standard BioTools Inc

Will Robinhood Markets ($HOOD) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Robinhood Markets Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

LAB
Standard BioTools Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest LAB News

LABStandard BioTools Inc